Nordic Randomized Phase III Trial of Two Different Durations of Adjuvant Therapy With Intermediate-dose Interferon Alfa-2b in Patients With High-risk Melanoma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 May 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Interferon alpha-2b (Primary)
Indications Malignant melanoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

22 Dec 2011 Results assessing the effects of treatment on health-related quality of life published in the European Journal of Cancer.
07 Jun 2011 Quality of life results (after 2 years) presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
20 Jan 2011 Results published in Lancet Oncology

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight